panbronchiolitis%20-%20diffuse
PANBRONCHIOLITIS - DIFFUSE
Diffuse panbronchiolitis is an inflammatory disease affecting the respiratory bronchioles.
It causes progressive suppurative and obstructive respiratory disease.
This is an idiopathic disease which is primarily found in Japan, Korea and China.
Predisposition to the disease may be genetically-related but environmental factors should also be considered.
Failure to treat diffuse panbronchiolitis can lead to development of bronchiectasis, progressive failure and death.

Panbronchiolitis - Diffuse Drug Information

Drug Information

Indication: Infections of nose-pharynx tract (tonsillitis, pharyngitis) & of paranasal sinuses; lower resp tract: bron...

Indication: Oral: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; acu...

Axcel Erythromycin ES
erythromycin ethylsuccinate

Indication: Upper & lower resp tract infections caused by Strep pyogenes & Strep pneumoniae; pertussis caused by B...

Indication: Lower & upper rest tract, skin & soft tissue infections, acute otitis media. STD, uncomplicated genita...

Indication: Lower resp tract infections eg, bronchitis & pneumonia, odontostomatological, skin & soft tissue infec...

Indication: Purulent bacterial & trachomatous conjunctivitis caused by Chlamydia trachomatis in adults & childn fr...

Indication: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; otitis me...

Indication: Nasopharyngeal, lower resp tract, skin & soft tissue infections.

Indication: Infections caused by clarithromycin-sensitive pathogens: Nasopharynx (eg, tonsillitis, pharyngitis), paranasal...

Indication: Upper resp tract infections eg, strep pharyngitis/tonsillitis, acute maxillary sinusitis; lower resp tract inf...

1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Elvira Manzano, 12 May 2020
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.

Christina Lau, 23 Jun 2020

Patients with coronavirus disease 2019 (COVID-19) have significant gut dysbiosis that persists even after viral clearance and resolution of respiratory symptoms, according to a metagenomic study by the Chinese University of Hong Kong (CUHK). These findings have led to the development of a probiotic supplement expected to be available in a few months.